Abstract:The chimeric oncoprotein Bcr-Abl is the causative agent of virtually all chronic myeloid leukemias and a subset of acute lymphoblastic leukemias. As a result of the so-called Philadelphia chromosome translocation t(9;22), Bcr-Abl manifests as a constitutively active tyrosine kinase, which promotes leukemogenesis by activation of cell cycle signaling pathways. Constitutive and oncogenic activation is mediated by an N-terminal coiled-coil oligomerization domain in Bcr (Bcr-CC), presenting a therapeutic target for inhibition of Bcr-Abl activity toward the treatment of Bcr-Abl+ leukemias. Previously, we demonstrated that a rationally designed Bcr-CC mutant, CCmut3, exerts a dominant negative effect upon Bcr-Abl activity by preferential oligomerization with Bcr-CC. Moreover, we have shown that conjugation to a leukemia-specific cell-penetrating peptide (CPP-CCmut3) improves intracellular delivery and activity. However, our full-length CPP-CCmut3 construct (81 aa) is encumbered by an intrinsically high degree of conformational variability and susceptibility to proteolytic degradation relative to traditional small-molecule therapeutics. Here, we iterate a new generation of CCmut3 inhibitors against Bcr-CC-mediated Bcr-Abl assembly designed to address these constraints through incorporation of all-hydrocarbon staples spanning i and i + 7 positions in α-helix 2 (CPP-CCmut3-st). We utilize computational modeling and biomolecular simulation to evaluate single- and double-stapled CCmut3 candidates in silico for dynamics and binding energetics. We further model a truncated system characterized by the deletion of α-helix 1 and the flexible loop linker, which are known to impart high conformational variability. To study the impact of the N-terminal cyclic CPP toward model stability and inhibitor activity, we also model the full-length and truncated systems devoid of the CPP, with a cyclized CPP, and with an open-configuration CPP, for a total of six systems that comprise our library. From this library, we present lead-stapled peptide candidates to be synthesized and evaluated experimentally as our next iteration of inhibitors against Bcr-Abl.

Inhibition of Abl Kinases by Intramolecular and Intermolecular Interactions: A Lesson from Structure Studies and CML Therapy

Structure-guided drug design targeting Abl kinase: how structure and regulation can assist in designing new drugs

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

Recent Advances In Bcr-Abl Tyrosine Kinase Inhibitors For Overriding T315i Mutation

Progress of the BCR-ABL and Src family kinases interactions leading CML to imatinib-resistance

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

Bcr-Abl Inhibitory Activities of Imatinib Derivatives

Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors

Bcr-Abl Inhibitors As Sensitizing Agents For Cancer Chemotherapy

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation

Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia

In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase

In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia

Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire

Targeting of BCR-ABL: Lessons Learned from BCR-ABL Inhibition.

In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs

Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML